These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

691 related items for PubMed ID: 19250201

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A.
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [Abstract] [Full Text] [Related]

  • 23. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG.
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [Abstract] [Full Text] [Related]

  • 24. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 25. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F.
    Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C.
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [Abstract] [Full Text] [Related]

  • 28. Extended adjuvant endocrine therapy of early breast cancer.
    Chowdhury S, Ellis P.
    Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
    Monnier A.
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
    Iwase H.
    Breast Cancer; 2008 Oct; 15(4):278-90. PubMed ID: 18810576
    [Abstract] [Full Text] [Related]

  • 36. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA, Land SR.
    Menopause; 2008 Oct; 15(4 Suppl):797-803. PubMed ID: 18596601
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Aromatase inhibitors and breast cancer.
    Miller WR.
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.